May 5, 2023 – Quest Diagnostics announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline.
The RestoreU service employs artificial intelligence (AI) developed by uMETHOD to create personalized care plans aimed at helping physicians improve patient care while also satisfying cognitive care guidelines*. The service incorporates results of laboratory tests ordered by physicians from Quest Diagnostics along with the patient’s health history, including comorbidities, lifestyle habits and medications. uMETHOD’s AI platform then assesses 50-plus risk factors, pinpointing areas of concern and ultimately generating a personalized care plan with evidence-based, actionable treatment recommendations.
With insights from the report, physicians may identify potentially reversible causes of cognitive decline, such as medication side effects or hormonal imbalances, that mimic dementia. The report may also help identify measures to potentially slow or, if possible, halt dementia disease progression.
The RestoreU service complements Quest’s comprehensive portfolio of dementia laboratory services, featuring the company’s advanced AD-Detect Amyloid Beta (AB) 42/40 Ratio blood test for assessing risk of Alzheimer’s disease. RestoreU can help the physician further refine this risk assessment, identify alternative possible causes of cognitive dysfunction and inform care.